Skip to main content
Clinical Trials/NCT04320459
NCT04320459
Completed
Not Applicable

Alexithymia in Ankylosing Spondylitis

Istanbul Medeniyet University1 site in 1 country110 target enrollmentFebruary 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ankylosing Spondylitis
Sponsor
Istanbul Medeniyet University
Enrollment
110
Locations
1
Primary Endpoint
Alexithymia rate in AS patients and controls according to Toronto Alexithymia Scale-20
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The study included 55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic and 55 healthy subjects. Demographic data were recorded for 55 AS patients who were subsequently assessed using the BASMI (Bath Ankylosing Spondylitis Metrology Index) in terms of elasticity and spinal mobility as well as the BASFI (Bath Ankylosing Spondylitis Functional Index) to determine functional status, the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) to assess the disease activity and the ASQoL (Ankylosing Spondylitis Quality of Life Questionnaire) to evaluate quality of life. The Toronto Alexithymia Scale-20 (TAS-20) was used for assessment of alexithymia and Beck's Depression Inventory (BDI) for depression among patients.

Detailed Description

The study included 55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic and 55 healthy subjects. Demographic data were recorded for 55 AS patients who were subsequently assessed using the BASMI (Bath Ankylosing Spondylitis Metrology Index) in terms of elasticity and spinal mobility as well as the BASFI (Bath Ankylosing Spondylitis Functional Index) to determine functional status, the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) to assess the disease activity and the ASQoL (Ankylosing Spondylitis Quality of Life Questionnaire) to evaluate quality of life. The Toronto Alexithymia Scale-20 (TAS-20) was used for assessment of alexithymia and Beck's Depression Inventory (BDI) for depression among patients.

Registry
clinicaltrials.gov
Start Date
February 1, 2016
End Date
August 15, 2016
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Istanbul Medeniyet University
Responsible Party
Principal Investigator
Principal Investigator

Bilinç Doğruöz Karatekin

MD, Research Assistant of PMR

Istanbul Medeniyet University

Eligibility Criteria

Inclusion Criteria

  • Diagnosed as AS for at least 1 year according to the ASAS classification criteria
  • over 18 years old

Exclusion Criteria

  • fibromyalgia
  • age less than 18 years
  • vision and hearing impairment
  • neurological disease (Parkinson's disease, multiple sclerosis, cerebrovascular disease),
  • history of a psychiatric disorder (schizophrenia, bipolar disorder)
  • history of chronic condition (DM, thyroid disease) or malignancy

Outcomes

Primary Outcomes

Alexithymia rate in AS patients and controls according to Toronto Alexithymia Scale-20

Time Frame: 7 months

Depression rate in AS patients and controls according to Beck Depression Inventory

Time Frame: 7 months

Relationship between alexithymia and depression and functional indexes (BASFI, BASMI, BASDAI, ASQoL)

Time Frame: 7 months

Study Sites (1)

Loading locations...

Similar Trials